Infusion Pumps Market Forecast 2014-2024: Prospects for Leading Companies

LONDON, Dec. 2, 2014 /PRNewswire/ -- Report DetailsInfusion pumps – new study showing you trends, R&D progress, and predicted revenuesWhere is the infusion pumps market heading? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.Our 216-page report provides 127 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing medical devices market.

Forecasts from 2014-2024 and other analyses show you commercial prospectsBesides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), leading products, competing technologies and commercial developments.Read the full transcripts of an exclusive interview with Professor Charles Clark, Former Associate Dean at Indiana University School of Medicine, and current medical director of two diabetes centres in two major Chinese Hospitals.

Discover sales predictions for the world market and submarketsAlong with revenue prediction for the overall world market, you see forecasts to 2024 for these three submarkets:- Insulin pumps- Enteral feeding pumps- Other infusion pumps, including chemotherapy an PCA pumpsWith our investigation you gain business research and analysis with individual sales predictions and discussions. You find analysis of competition, as well as commercial drivers and restraints affecting each submarket. See what's likely to achieve the most success.You gain competitive advantages by understanding the dynamics, opportunities and challenges facing the infusion pumps market.Our analysis also breaks down the submarkets by geography to derive the national market share within each submarket.

What are the prospects in the leading regions and countries?In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 national markets to 2024:- US- Japan- China- Germany- France- UK- Italy- Spain- Rest of Europe- India- Brazil- Russia- South Korea- Rest of the WorldThere will be growth in established and developing medical devices markets. Our analyses show that India, China, South Korea and Brazil, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and patient demographics will influence the infusion pumps market.There exist many opportunities for medical device companies developing infusion pump technologies. You can assess the industry's future - hear about developments and find their significance in our analytical report.

See revenue forecasts for competing drug delivery technologiesHow will competing drug delivery technologies perform to 2024 at world level? Our study forecasts the sales revenue of global drug delivery technologies market as well as the submarkets by application for the period 2014-2024. Submarkets included in the forecast are:- Oral drug delivery- Inhalation drug delivery- Injectable/ implants drug delivery- Transdermal drug delivery- Ocular drug delivery- Nasal drug deliveryDiscover how high revenues can go. You see what's happening, understanding trends, challenges and opportunities.

Leading products and companiesWhat will happen next? We predict the overall world market for infusion pumps will reach $8.20bn in 2015, and expand further to 2024.Our study shows you what technologies, products and companies hold greatest potential. The report contains reviews of 32 leading infusion pumps on the market and their manufacturing companies.From 2014 to 2024, many opportunities will arise. Our work shows you the technological and commercial possibilities, helping you stay ahead.

Research and development - assess innovation, trends and possibilitiesWhat about R&D - the pipeline for new infusion pumps? You will see further 15 pipeline products currently under development by big players in the infusion pumps marketOur study also discusses key R&D pipeline for narcotic pain relieving drugs, which are often used in PCA infusion therapies, as well as the pipeline for drug delivery technologies by application.Insulin pumps are currently the most dynamic submarket within the infusion pumps market in terms of its wealth of technological innovations and R&D pipeline. Cost-effective, safe and portable pumps are in great demand. We see the next generation of new smart pumps dictating the infusion pumps market in the years to come.

What issues will affect the infusion pumps market?Our new report discusses issues and events affecting the infusion pumps market from 2014, looking ahead. You will find discussions, including qualitative analyses:- Shifting dynamics in the infusion pumps market- Escalating levels of worldwide chronic diseases including diabetes and cancer- Reimbursement outlook in key segments of the market- Strengths and weaknesses of the infusion pumps market- The microenvironment in which companies operateAlso, you find coverage of these aspects:- New European Medical Devices Regulations- Competition from pharmaceuticals and other drug delivery technologies- Regulatory harmonisation across major international markets- Expanding healthcare coverage in emerging marketsYou will see discussions of technological, commercial, economic and political matters, with emphasis on the competitive landscape and business outlooks.

How the Infusion Pumps Market Forecast 2014-2024: Prospects for Leading Companies report helps youIn summary, our new 219-page comprehensive report gives you the following knowledge:- Revenues forecast to 2024 for the world infusion pumps market and submarkets– discover the industry's prospects, finding promising places for investments and revenues- Revenue forecasts to 2024 for the leading 12 national markets – US, Japan, China, Germany, France, UK, Italy, Spain, Rest of Europe, India, Brazil, Russia, South Korea and Rest of the World- Reviews of 32 leading infusion pumps on the market – hear about products, results and strategies.- Review of 15 pipeline products under development – investigate developmental trends and progress- Revenue forecasts to 2024 of competing drug delivery technologies – you find activities, products, capabilities and outlooks- Discussion of what stimulates and restrains the industry and market – you assess challenges and strengths- Understanding of competition and opportunities – you see what affects that industry, learning what shapes its future- Analysis of microenvironment – helping you compete and gain advantages- Prospects for established firms and those seeking to enter the market – you explore needs, practices and outlooks for success- View interview transcripts with a market expert – gain exclusive market insightsYou will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere elseWe give independent analysis from our primary and secondary research. You will receive business intelligence found only in our study, seeing where prospects are lucrative and growth is likely.With our report you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions, saving you time and getting you recognition for commercial insight.Discover technological and commercial prospects from 2014 by ordering nowVisiongain's study is for everyone needing analysis of the industry and market for infusion pumps. You find data, trends and predictions. Please ask for our report now.

Download the full report: https://www.reportbuyer.com/product/2512631/

About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com  Tel: +44 208 816 85 48 Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/infusion-pumps-market-forecast-2014-2024-prospects-for-leading-companies-300003461.html

SOURCE ReportBuyer

http://www.medindia.net/health-press-release/infusion-pumps-market-forecast-2014-2024-prospects-for-leading-companies-230819-1.htm
Read more:  Infusion Pumps Market Forecast 2014-2024: Prospects for Leading Companies http://www.medindia.net/health-press-release/Infusion-Pumps-Market-Forecast-2014-2024-Prospects-for-Leading-Companies-230819-1.htm#ixzz3KlMnZA5l

The Michael J. Fox Foundation for Parkinson's Research Launches The Edmond J. Safra Fellowship in Movement Disorders

Fellowship Program Building a Workforce of Parkinson's Disease Care and Research Specialists

NEW YORK, Dec. 2, 2014 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research, in collaboration with its longtime supporter and partner The Edmond J. Safra Foundation, announces The Edmond J. Safra Fellowship in Movement Disorders. By increasing resources for specialized training for clinician-researcher neurologists, the program aims to grow the global base of movement dis

order specialists treating people with Parkinson's disease (PD) and contributing to research toward breakthrough treatments for the disease.

"Lily Safra has long shown tremendous compassion to people living with disease, both through her personal generosity and the activities of The Edmond J. Safra Foundation," said Michael J. Fox. "We're grateful to be working together to increase the number of highly specialized neurologists who can help patients live better with PD and speed progress toward a cure."

Mrs. Lily Safra, Chairwoman of The Edmond J. Safra Foundation, said: "The talented young clinician-researchers who will be chosen as Edmond J. Safra Fellows represent great hope for all of us, and I am so proud to be supporting them at the beginning of what will certainly be stellar careers full of groundbreaking achievements. With The Michael J. Fox Foundation's leadership, this initiative will surely make a profound impact on both research and patient care in the years to come."

Todd Sherer, PhD, CEO of The Michael J. Fox Foundation (MJFF), added: "This program holds potential to benefit not only the five million Parkinson's patients and families worldwide, but also the millions more living with essential tremor, dystonia and other movement disorders. Clinician-researchers are an important bridge between positive patient outcomes in the care setting and scientific advances in the lab."

A lack of available funding for fellowships currently limits the number of openings in movement disorder specialist training programs, including programs at medical centers with the required expertise to train the next generation of specialists.

"Unfortunately, more people want to enter the field than there is funding to allow. Many fellows are unable to specialize in an area that is only going to grow in demand," said Matthew B. Stern, MD, director of the Parkinson's Disease and Movement Disorders Center at the University of Pennsylvania Health System and president of the International Parkinson and Movement Disorder Society (IPMDS).

The Edmond J. Safra Fellowship in Movement Disorders is launching as a pilot program, supporting up to five new fellows a year for two years. Fellowships will be granted to multiple centers in each round of funding. Interested movement disorder centers may submit applications to MJFF through January 28, 2015.

Impact of Clinician-Researchers Specializing in Movement Disorders

In addition to delivering expert care to individual patients, clinician-researcher movement disorder specialists improve the landscape of Parkinson's care overall. The clinicians trained through The Edmond J. Safra Fellowship in Movement Disorders also will be researchers, designing and conducting studies with their patients' unmet needs in mind. From the front lines, they are poised to observe trends and nuances of the patient experience that can lead to investigations toward greater understanding of disease and open new avenues to better therapies.

Patients are also specialists' greatest partners in research. These doctors are aware of (and often leaders of) ongoing clinical trials and research studies, putting them in a position to educate their patients about participating in research — a powerful opportunity to be part of the quest for a cure.

"Parkinson's research and care is a two-way street, with ideas and techniques flowing from each to inform the other. Movement disorder specialists are the streets, sharing insights from the bench to the bedside and back," said Stern.

Dedication to Parkinson's Care and Research
Founded by the late banker and philanthropist Edmond J. Safra, his namesake Foundation has long supported Parkinson's disease care and research. Mr. Safra is survived by his wife, Lily Safra, who has been a member of MJFF's Board of Directors since 2001 and serves as chairwoman of The Edmond J. Safra Foundation.

In addition to generous gifts to centers and programs providing direct care to people with Parkinson's disease, Lily Safra and her Foundation have driven vital scientific investigation into new treatments through The Edmond J. Safra Core Programs for PD Research, one of MJFF's central grantmaking programs to support high-impact Parkinson's research projects.

For More Information

MJFF will hold a conference call on January 7, 2015 to explain the goals of this initiative in greater detail and answer applicant questions. Fellowship and sponsored programs administrators at movement disorder centers are encouraged to take part (as are members of neurology departments). To receive call-in details, RSVP to conferencecalls@michaeljfox.org.

About The Edmond J. Safra Philanthropic Foundation
Edmond J. Safra was one of the 20th century's most accomplished bankers, as well as a devoted philanthropist. He created a major philanthropic foundation to ensure that needy individuals and organizations would continue to receive assistance and encouragement for many

years to come. Now under the chairmanship of his beloved wife Lily, The Edmond J. Safra Philanthropic Foundation draws continuing inspiration from its founder's life and values. Through Mrs. Safra's leadership since 1999, the Foundation supports hundreds of projects related to education, science and medicine, religion, culture and humanitarian relief in over 40 countries. The Foundation has provided significant funding for Parkinson's disease research and patient care at dozens of hospitals and institutes in places as varied as Natal (Brazil), Toronto, New York, Grenoble, Paris, London and Jerusalem.

For more information, visit www.edmondjsafra.org.

About The Michael J. Fox Foundation for Parkinson's Research
As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers.  In addition to funding more than $450 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.

For more information, visit us on the Web, Facebook, Twitter, LinkedIn and Pinterest.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-michael-j-fox-foundation-for-parkinsons-research-launches-the-edmond-j-safra-fellowship-in-movement-disorders-300002848.html

SOURCE The Michael J. Fox Foundation for Parkinson's Research

Teikoku Pharma USA Announces Positive Study Results of 7-Day Patch for Parkinson's Disease

SAN JOSE, Calif., Dec. 2, 2014 /PRNewswire/ -- Teikoku Pharma USA announced positive results of a recently completed bioavailability (BA) study examining the delivery of TPU-002RA, a 7-day rasagiline patch, for Parkinson's disease. This study was part of the U.S. Food and Drug Administration (FDA) recommended program for a 505(b)(2) New Drug Application (NDA) for TPU-002RA and will be a critical component of this product's NDA.

The study confirmed that one patch of rasagiline applied for 7 days achieved a higher systemic exposure than that of AZILECT® (rasagiline) 1mg tablets administered orally once daily for 7 days. Additionally, the patch produced more consistent blood levels of rasagiline throughout the 7 day period, without any significant peaks as seen with the oral product.

Paul Mori, Executive Vice President and COO said, "We are pleased to have demonstrated the ability of our unique transdermal drug delivery technology to provide systemic drug exposure equivalent or greater than the oral product at its therapeutically effective dose. The patch offers the potential for improved medication adherence and reduction of caregiver workload." He continued, "The outcome of this study not only satisfies the FDA's request, but also enhances the probability of success for a patient-friendly rasagiline product."

About the Parkinson's Disease Market

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease. There are between 1 and 1.5 million Americans living with Parkinson's disease.1 Worldwide patient population is estimated to 4 million and projected to grow to over 9 million cases.2,3 The main symptoms (stiffness, tremors, and slowed movements and gait) are caused by a loss of dopamine production by the neurons that are involved in controlling movement and coordination. 4,5 Overall, world revenue for drugs treating PD will reach $3,426M in 2016.5,6 There are 8 major anti-Parkinson drugs in U.S. market with MIRAPEX®, Carbidopa/levodopa, and REQUIP®. AZILECT® had 2013 sales of $240M in the US and $248M for Europe and Asia market, and is still enjoying sales growth of 19.4% growth in the US.7,8

Besides the foremost need to develop a therapy to slow Parkinson's disease progression, several other important needs exist:

• Alternative delivery systems to counter difficulty swallowing;
• New less side-effect laden drugs for the delay of onset of dementia;
• Cure that repairs and/or reverses the damage; and
• Simplification of complex medical regimens. 

About TPU-002RA

TPU-002RA is being developed for the treatment of Parkinson's disease. This product uses Teikoku's unique transdermal patch system and contains the same active drug component in AZILECT®, the only currently marketed form of rasagiline. Teikoku believes that our TPU-002RA offers potential advantages over AZILECT® oral and could seize a meaningful share of this rapidly growing market.

About Teikoku Pharma USA 

Teikoku Pharma USA Inc.("TPU"), a wholly owned subsidiary of Teikoku Seiyaku Co., Ltd. of Japan, is an international specialty pharmaceutical company that develops and manufactures pharmaceutical products based on our delivery platform technologies. 

TPU is the NDA holder of LIDODERM® (Lidocaine 5% Patch) for post herpetic neuralgia (PHN), and Lidoderm is currently distributed by Endo Pharmaceuticals in the US, Grünenthal GmbH mainly in Europe, South America and Oceania, and other distributers in Asia.

Teikoku's internal therapeutic focus is addressing unmet medical needs in the pain management, central nervous system, and oncology categories.

For more information please contact: Francisco Bejar at fbejar@teikokuusa.com

Finding balance: Class helps Parkinson's patients manage disease

November 29, 2014 5:00 am  •  Molly Barari Journal correspondent

Every Friday from 11:45 a.m. to 1 p.m., Bill Van Heukelem splashes his way through the Parkinson’s Wellness Recovery in Water class at the Roosevelt Swim Center. The 73-year-old was diagnosed with Parkinson’s disease 12 years ago, and the class has done wonders to help alleviate his symptoms.

“I enjoy the water class at the Swim Center because we can work on balance without fear of falling and learn how our arms, trunk and legs are all connected and work together to help us balance on land,” he said.

The Mayo Clinic describes Parkinson's as a progressive disorder of the nervous system that affects movement. The disease develops gradually, sometimes starting with a barely noticeable tremor in just one hand. In addition to tremors, the disorder also commonly causes stiffness or slowing of movement. There is no cure for the disease, and it affects each person differently.

“Parkinson's disease not only affects movement but also interferes with things that others can't see, such as the digestive system, vascular system, sense of smell, and ability to sleep,” said Van Heukelem. “I have given up hunting because I can no longer hold the gun steady and my reaction time is slower and less predictable. I gave up golfing because I was too uncoordinated.”

Van Heukelem said he’s less affected by his symptoms when he’s riding his horse or exercising, which is why he makes time for the weekly water class. He appreciates that class instructor Bjo Schreier is knowledgeable about the bio-mechanics of Parkinson’s disease.

“She teaches us how to move efficiently and tone our muscles to increase our fitness and endurance,” he said. “She makes the class fun and makes us feel like teammates, so it’s interactive and as much a social event as it is a workout. We learn that we can do much more than we and our friends thought we could.”

According to Schreier, the class is designed to have dynamic movements. “We took our class to the water for more stability and more resistance (strength) work. It allows for fun falling. We practice super sounds – word groupings that require tricky diction – to help with learning the sensations of speech, both diction and volume. We also do memory work. Everyone picks a name of a vehicle and we throw the ball to someone calling his name. All our classes require very mindful attention in order to reestablish new neuro-pathways.”

Schreier said she’d like to cut through the stigma associated with Parkinson’s. “If you hear that you have Parkinson’s disease, your life is not destroyed; it is redesigned. I’d like the community to know that those with Parkinson’s are not mentally retarded, drunk nor disinterested. These are symptomatic conditions and the person is same person masked underneath these characteristics. It is our joyful duty to continue to relate to the person and not to his condition in order to continue relationships.”

Van Heukelem’s wife, Laurie, said people often don’t understand that those with Parkinson’s disease speak slower and quieter than others. It’s important to encourage them to speak louder and to take their time. She also said facial muscles are affected, so it takes more prompting to elicit a smile or other expression.

“Our grandson is the best at making Bill smile,” she said. “As Bill’s disease progresses, we come across bumps in the road, so to speak, but then we tend to adapt and seek ways to improve the quality of our lives. It is important for care partners to seek support from others who live with those who have Parkinson’s.”

http://health.einnews.com/article/237212179/totVGKcBW8Ugt_j3?n=2&code=ga_qGBxHZ2aVYO4P

Possible Disease-Modifying Therapy for Parkinson’s One Step Closer to Patients

FoxFeed Blog

Posted by  Rachel Dolhun, MD, November 26, 2014

CBS News in New York shined a spotlight on Parkinson’s research yesterday evening — for good reason.  A promising disease-modifying therapy is getting closer to reaching people with Parkinson’s.  

Isradipine — a medication currently approved to treat high blood pressure — is being studied to determine if it can influence the course of Parkinson’s disease (PD). Researchers believe the drug works to prevent the death of dopamine-producing cells and therefore might slow the progression of disease. Previous studies have confirmed drug safety and tolerability so testing will now move into a Phase III clinical trial — the largest, and last, stage of drug development testing. The STEADY-PD trial is recruiting over 300 participants with early PD, each of whom will take either isradipine or placebo and be monitored for three years.

Todd Sherer, CEO of The Michael J. Fox Foundation, told CBS News that isradipine is one of several active research areas in Parkinson’s. The Foundation has invested millions in helping to advance isradipine from the earliest testing in preclinical models to the current Phase III trial testing. Positive results from this study would move a disease-modifying therapy for Parkinson’s one step nearer to pharmacy shelves.

See if you are eligible for ongoing clinical trials by completing a profile on Fox Trial Finder.

Ryan Reynolds, Michael J. Fox team up to find Parkinson's cure

Lisa FlamTODAY

Ryan Reynolds and Michael J. Fox have been starring together for years now — not in front of the camera, but as friends united in the personal goal of finding a cure for Parkinson’s disease.

Reynolds got involved with the Michael J. Fox Foundation for Parkinson’s Research in 2008, and has since joined the organization’s board of directors. Like Fox, Reynolds’ father has had the disease for many years.

Video: The two actors sit down with Willie Geist to talk about working together to help find a cure for Parkinson’s disease. Reynolds’ father also suffers from the illness.

FoxFeed Blog

TODAY SHOW: Michael J. Fox, Ryan Reynolds Talk Family and Parkinson's

Posted by  Elizabeth Joyce, November 26, 2014

This morning on NBC's Today Show, Willie Geist sat down with Michael J. Fox and Ryan Reynolds to talk about a shared connection: both Willie's and Ryan's fathers have Parkinson's. Characteristically upbeat, the interview had Ryan joking that he was wearing his Michael J. Fox Foundation underwear in support. "For these two, laughter is medicine," said Willie. And, on his father's diagnosis, Ryan said, "It kind of galvanized everyone else [in our family] to seek resources, and in a strange way it's really brought us together."

The actors sat down with TODAY’s Willie Geist, whose dad also has Parkinson’s, before the Fox foundation’s annual gala in New York on Saturday. 

Geist asked Reynolds if he remembered his father telling him and his brothers that he had Parkinson’s, a degenerative disease with motor symptoms that include tremors, rigidity and balance problems.

“I have a slightly different, weird, strange story about that because my father really hasn't ever said he has Parkinson's disease,” Reynolds said with a laugh, adding that his dad is in his 70s.

“He comes from a pretty prideful generation,” he said. “And he doesn't really talk about it too much. But, he’s maybe said it once or twice out loud.”

Still, Jim Reynolds’ 1995 diagnosis helped rally the family.

“It kind of galvanized everybody else, to sort of seek resources,” the actor said. “And for us, it's in a strange way, it's really kind of brought us together.”

Geist, whose father, “CBS Sunday Morning” correspondent Bill Geist, revealed his two-decade-old diagnosis in 2012, agreed that Parkinson’s can bring people together.

“If there's any upside to it, it's that it has rallied an awful lot of people,” Geist said.

Fox was diagnosed in 1991 at age 29 but didn’t announce it publicly until 1998. He recalled keeping his diagnosis to himself and close family members at a time when he was at the height of his career, with a growing family.

“It’s a degenerative, progressive disease,” Fox said. “And,” he added, “also there's shame in illness.”

Now, Fox said that in his house, his family — he and his wife, Tracy Pollan, have four children — helps him by pulling a chair out a little bit for him. Reynolds joked that maybe they were doing that so the TV and film star would fall to the ground.

Though they can laugh, they also serious about finding a cure for the disease, which affects an estimated500,000 to 1 million Americans.

Geist noted that he wears a Fox foundation bracelet everywhere he goes. Reynolds said he was wearing “rubberized, galvanized Michael J. Fox underwear.”

As Fox has become almost as well known for being the force against Parkinson’s disease as he is for starring in “Back to the Future,” does he ever tire of being the public face of the disease?

“I really don't,” Fox said. “Once I made my diagnosis known, it’s been a tremendous opportunity and a tremendous privilege.”

For more information on the Michael J. Fox Foundation for Parkinson’s Research, visithttps://www.michaeljfox.org/

Lisa A. Flam is a news and lifestyles reporter in New York. Follow her on Twitter.